Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2023; 11(27): 6664-6669
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6664
Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report
Sang Jae Lee, Si-Youn Song, Min Kyoung Kim, Hyung Gyun Na, Chang Hoon Bae, Yong-Dae Kim, Yoon Seok Choi
Sang Jae Lee, Si-Youn Song, Hyung Gyun Na, Chang Hoon Bae, Yong-Dae Kim, Yoon Seok Choi, Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Yeungnam University, Daegu 42415, South Korea
Min Kyoung Kim, Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu 42415, South Korea
Yong-Dae Kim, Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu 42415, South Korea
Author contributions: Lee SJ and Choi YS contributed to the conceptualization, data curation, and writing-review & editing; Bae CH and Na HG contributed to the formal analysis; Song SY and Choi YS contributed to the funding acquisition; Bae CH and Song SY contributed to the investigation; Kim MK and Choi YS contributed to the methodology and supervision; Kim YD and Bae CH contributed to the project administration; Lee SJ and Na HG contributed to the visualization; Lee SJ wrote the original draft.
Supported by the 2023 Yeungnam University Research Grant.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors have nothing to disclose pertaining to this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yoon Seok Choi, MD, PhD, Associate Professor, Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Yeungnam University, 170, Hyeonchung-ro, Nam-Gu, Daegu 42415, South Korea. choiys@ynu.ac.kr
Received: July 26, 2023
Peer-review started: July 26, 2023
First decision: August 16, 2023
Revised: August 24, 2023
Accepted: August 31, 2023
Article in press: August 31, 2023
Published online: September 26, 2023
Processing time: 56 Days and 10.1 Hours
Core Tip

Core Tip: Anaplastic thyroid cancer (ATC) is a rare but aggressive type of thyroid carcinoma. The BRAF V600E-mutation, found in 10%-50% of ATCs, is associated with a poor prognosis. A recent clinical trial reported a substantial clinical benefit of dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in treating BRAF V600E-mutant ATC. This report highlights the therapeutic potential of dabrafenib plus trametinib as an adjuvant chemotherapy to treat and prevent the recurrence of ATC confirmed with BRAF mutation following surgical resection.